Maximum Life's Product Navitol Clinically Proven to Reduce Systolic Blood Pressure

A series of studies show that one of the active ingredients in Navitol contributes to promoting healthier blood circulation and heart health by improving blood vessel responsiveness and reducing systolic blood pressure. The superior blend of extracts in Navitol were carefully studied and selected to provide both specific and synergistic funcitons.

Sudbury, Ontario (PRWEB) March 27, 2008 -- A series of studies show that one of the active ingredients in Navitol contributes to promoting healthier blood circulation and heart health by improving blood vessel responsiveness and reducing systolic blood pressure. The superior blend of extracts in Navitol were carefully studied and selected to provide both specific and synergistic functions.

According to the American Heart Association, 1 in 3 Adults have high blood pressure and data from the National Health and Nutritional Examination survey 199-2004 shows that the estimated prevalence of high blood pressure in adults aged 20 and older in the United States is now 72 million. The active ingredient in Navitol was shown to significantly reduce systolic blood pressure within 6 weeks of supplementation. To view a summary of the study, click here (http://www.mln.ca/en/pdfs/enzo_bloodpressure.pdf).

Maximum Life Nutraceuticals Inc. (http://mln.ca) continues to recieve significant research contributions from its Scientific Advisory Board led by Dr. Anthony Martin. The company is excited by the results of these ongoing clinical studies.

###